RT Journal Article SR Electronic T1 Cutaneous Leishmania mexicana Infections in the United States: Defining Strains Through Endemic Human Pediatric Cases in Northern Texas JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.01.11.23300611 DO 10.1101/2024.01.11.23300611 A1 Nepal, Binita A1 McCormick-Baw, Clare A1 Patel, Karisma A1 Firmani, Sarah A1 Wetzel, Dawn M. YR 2024 UL http://medrxiv.org/content/early/2024/02/15/2024.01.11.23300611.abstract AB Over a six-month span, three patients under five years old with cutaneous leishmaniasis presented to the Pediatric Infectious Diseases Clinic at the University of Texas Southwestern Medical Center/Children’s Health Dallas. None had traveled outside of the United States (US); all had confirmed L. mexicana infections by PCR. We provide case descriptions and images to increase the awareness of this disease among US physicians and scientists. Two patients responded to fluconazole, but one required topical paromomycin. Combining these cases with guidelines and our literature review, we suggest that: 1) higher doses (ten-twelve mg/kg/day) of fluconazole should be considered in young children to maximize likelihood and rapidity of response and 2) patients should transition to alternate agents if they do not respond to high-dose fluconazole within six weeks. Furthermore, and of particular interest to the broad microbiology community, we used samples from these cases as a proof-of-concept to propose a mechanism to strain-type US-endemic L. mexicana. For our analysis, we sequenced three housekeeping genes and the internal transcribed sequence 2 of the ribosomal RNA gene. We identified genetic changes that not only allow us to distinguish US-based L. mexicana strains from strains found in other areas of the Americas, but also establish polymorphisms that differ between US isolates. These techniques will allow documentation of genetic changes in this parasite as its range expands. Hence, our cases of cutaneous leishmaniasis provide significant evolutionary, treatment and public health implications as climate change increases exposure to formerly tropical diseases in previously non-endemic areas.IMPORTANCE Leishmaniasis is a parasitic disease that typically affects tropical regions worldwide. However, the vector that carries Leishmania is spreading northward into the United States (US). Within a six-month period, three young cutaneous leishmaniasis patients were seen at the Pediatric Infectious Diseases Clinic at The University of Texas Southwestern/Children’s Health Dallas. None had traveled outside of north Texas. We document their presentations, treatments, and outcomes and compare their management to clinical practice guidelines for leishmaniasis. We also analyzed the sequences of three critical genes in Leishmania mexicana isolated from these patients. We found changes that not only distinguish US-based strains from strains found elsewhere, but also differ between US isolates. Monitoring these sequences will allow tracking of genetic changes in parasites over time. Our findings have significant US public health implications as people are increasingly likely to be exposed to what were once tropical diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Nepal is funded by American Heart Association Postdoctoral Fellowship 916875. Dr. Wetzel is supported by a Childrens Clinical Research Advisory Committee (CCRAC) Early Investigator Award, a 2019 Harrington Scholar-Innovator Award, NIH R01 AI146349, and a Welch Grant for Chemistry (I-2086).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB at University of Texas Southwestern Medical Center declared that since a small number of cases were described, their report was exempt from IRB approval. The University of Texas Southwestern IRB gave ethical approval for the clinical research described in this manuscript (STU-2019-0754).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are contained in the manuscript or will be available upon reasonable request to the authors.